Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C24H29N7O2 · xHCl
CAS Number:
Molecular Weight:
447.53 (free base basis)
MDL number:
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear (warmed)
storage temp.
-10 to -25°C
Quality Level
General description
Potent oral CDK4/6 inhibitor induces reversible G1 arrest by blocking Rb phosphorylation, suppressing cancer proliferation and extending survival.
Palbociclib (PD 0332991), an oral, cell-permeable, ATP-competitive dual CDK4/6 inhibitor, arrests G1-S transition by preventing Rb phosphorylation and E2F sequestration. Its high specificity is evidenced by nanomolar IC50s (CDK4/D1: 11 nM; CDK4/D3: 9 nM; CDK6/D2: 15 nM) versus >5 µM for other CDKs (CDK1/2/5) and minimal broader kinase activity. This reversible G1 arrest reduces proliferation, induces senescence, and decreases tumor burden preclinically. Its targeted inhibition of a key cell cycle regulator offers a pivotal advantage over broad cytotoxic agents, mitigating systemic toxicities, demonstrating robust efficacy, and clinically translating to increased PFS in HR+/HER2- metastatic breast cancer with endocrine therapy. Moreover, its recent identification as a direct STING dimerization/activation inhibitor implies novel repurposing in autoinflammatory diseases and enhancing anti-tumor immunity, extending utility beyond cell cycle.
Palbociclib (PD 0332991), an oral, cell-permeable, ATP-competitive dual CDK4/6 inhibitor, arrests G1-S transition by preventing Rb phosphorylation and E2F sequestration. Its high specificity is evidenced by nanomolar IC50s (CDK4/D1: 11 nM; CDK4/D3: 9 nM; CDK6/D2: 15 nM) versus >5 µM for other CDKs (CDK1/2/5) and minimal broader kinase activity. This reversible G1 arrest reduces proliferation, induces senescence, and decreases tumor burden preclinically. Its targeted inhibition of a key cell cycle regulator offers a pivotal advantage over broad cytotoxic agents, mitigating systemic toxicities, demonstrating robust efficacy, and clinically translating to increased PFS in HR+/HER2- metastatic breast cancer with endocrine therapy. Moreover, its recent identification as a direct STING dimerization/activation inhibitor implies novel repurposing in autoinflammatory diseases and enhancing anti-tumor immunity, extending utility beyond cell cycle.
Disclaimer
Hygroscopic Store with desiccant
signalword
Warning
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 2 - Muta. 2 - Repr. 2 - Skin Sens. 1B - STOT RE 2 Oral
target_organs
Bone marrow,male reproductive organs
Storage Class
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service